
biote Corp.
99
Recent developments include quarterly earnings calls and reports for Q3 and Q2 2026, share repurchase activity, and amendments to credit agreements.
- biote Corp. reported net income of $407,000 and EPS of $0.01 for Q3 2026, with earnings call details available [N1].
- The company announced Q3 2026 earnings that topped estimates, indicating positive financial performance for the quarter [N2].
- Q2 2026 earnings call highlighted break-even earnings and operational updates [N3][N4][N5].
- In Q1 2026, earnings and revenues lagged estimates, reflecting some variability in financial results [N6][N7].
- biote repurchased 621,498 shares of Class A common stock during Q3 2026 for $1.4 million, with $3.8 million remaining authorized for repurchase [S2].
- On November 4, 2026, the company executed a first amendment to its credit agreement, waiving noncompliance with financial covenants for the period ended September 30, 2026 [S2].
biote Corp. provides a comprehensive hormone optimization platform known as the Biote Method, which includes education, certification, practice management software, inventory management, and marketing support for healthcare practitioners specializing in bioidentical hormone replacement pellet therapy. The company also markets a line of Biote-branded dietary supplements. Its go-to-market strategy focuses on expanding the network of Biote-certified practitioners and supporting their practice growth through mentorship, marketing, and consumer referrals. The company leases office and clinic facilities primarily in Texas and Alabama. biote has been publicly traded under the ticker BTMD since May 2022.
Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. biote Corp. operates a hormone optimization platform training healthcare providers in bioidentical hormone replacement therapy and supporting their practices with software, marketing, and supplements. The company reported net income of $407,000 and EPS of $0.01 for Q3 2026, with liquidity ratios indicating moderate short-term financial strength as of September 30, 2026. The business model is supported by a network of certified practitioners and a branded supplement line. The company faces ongoing legal proceedings and operates under credit agreements with financial covenants that may constrain flexibility.
The company's integrated platform and practitioner network create a scalable model for growth in the hormone optimization market. Continued expansion of certified practitioners and increased sales of Biote-branded supplements could enhance revenue streams. The company's liquidity position and access to credit facilities provide financial resources to support operations and strategic initiatives. Ongoing digital marketing and consumer referral capabilities may further drive practitioner practice growth.
The company faces legal risks from ongoing litigation related to breach of contract and misappropriation claims, which could result in financial and operational impacts. Financial covenants in credit agreements may limit operational flexibility and increase refinancing risk. Variability in quarterly financial performance, including periods of break-even or lagging revenues, introduces earnings volatility. The absence of dividend payments may limit appeal to income-focused investors. Competitive pressures in the hormone optimization and supplement markets could affect growth prospects.
biote Corp.'s moat derives from its integrated platform combining practitioner training, certification, software tools, marketing support, and a branded supplement line, creating a differentiated end-to-end solution in the hormone optimization space. The established network of certified practitioners and the company's proprietary Biote Method provide barriers to entry for competitors. The company's long operating history and specialized focus contribute to its competitive positioning.
• Legal Proceedings: biote Corp. is involved in multiple ongoing lawsuits including breach of contract and misappropriation of name and likeness claims. Outcomes are uncertain and could materially affect financial condition and operations.
• Credit Agreement Covenants: The company's credit facilities include affirmative, negative, and financial covenants that may restrict business operations and strategic flexibility. Noncompliance could trigger defaults and accelerate debt repayment obligations.
• Earnings Volatility: Quarterly financial results have shown variability including break-even earnings and periods of revenue and earnings lagging expectations, contributing to operational uncertainty.
• Cybersecurity Risks: The company faces cybersecurity risks which are actively managed by the CIO and overseen by the board and audit committee, but remain a potential threat to business continuity and data protection.
Business trends: Expansion of Biote-certified practitioner network and growth in branded supplement sales underpin the business model.
Execution milestones: Ongoing quarterly earnings reporting, share repurchase program execution, and credit agreement amendments demonstrate active financial management.
Key risks: Legal proceedings, credit covenant constraints, earnings variability, and cybersecurity threats remain material considerations.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- biote Corp. operates in the hormone optimization space, training physicians and nurse practitioners in bioidentical hormone replacement pellet therapy for men and women with hormonal imbalance.
- The company provides a comprehensive platform called the Biote Method, which includes education, training, certification, practice management software, inventory management software, and marketing support for Biote-certified practitioners.
- biote sells a complementary line of Biote-branded dietary supplements, currently including 26 different products.
- The company focuses on increasing the number of Biote-certified practitioners through provider referrals, a dedicated sales force, and digital and traditional marketing channels targeting specific physicians by specialty and location.
- biote supports growth of practitioners' practices by providing mentorship, practice management, marketing capabilities, high-quality supplements, wellness education, and consumer referral via a 'Find A Provider' feature on its website.
- As of September 30, 2026, biote had cash and cash equivalents of $8.85 million and current assets of $41.76 million, with current liabilities of $30.5 million, resulting in a current ratio of 1.37 and a cash ratio of 0.95.
- The company reported net income of $407,000 and basic and diluted EPS of $0.01 for the quarter ended September 30, 2026.
- biote has a senior secured revolving credit facility of $35 million and a senior secured term loan credit facility of $125 million, with covenants that may limit operational flexibility; a recent amendment waived noncompliance with financial covenants for the period ended September 30, 2026.
- biote has a share repurchase program authorized for up to $20 million, with $3.8 million remaining available as of September 30, 2026, and repurchased 621,498 shares during Q3 2026.
- The company leases office and clinic facilities in Irving, Texas, and Birmingham, Alabama, with sufficient space for current needs.
- biote has been involved in several legal proceedings including lawsuits related to breach of contract, fraud, and misappropriation of name and likeness; some cases have been settled or dismissed, others remain pending with uncertain outcomes.
- The board of directors and Audit Committee actively oversee risk management including cybersecurity risks, with quarterly reports from the CIO and use of recognized industry frameworks for information security.
- biote's business model has been in operation for over 14 years and is described as differentiated and positioned for growth.
- Recent earnings calls and reports indicate quarterly financial results with some quarters reporting break-even or positive net income and others with revenues and earnings lagging estimates.
- The company has not declared or paid any cash dividends and does not anticipate paying dividends in the foreseeable future.
Generated 2026-11-10
- N1
- N3
- N6
- S1 | 2026-03-13 | 10-K
- S2 | 2026-11-09 | 10-Q
- N1 | 2026-11-05 | www.nasdaq.com | biote Corp. (BTMD) Q3 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/biote-corp-btmd-q3-2026-earnings-call-transcript
- N2 | 2026-11-04 | www.nasdaq.com | biote Corp. (BTMD) Tops Q3 Earnings Estimates | https://www.nasdaq.com/articles/biote-corp-btmd-tops-q3-earnings-estimates
- N3 | 2026-08-12 | www.nasdaq.com | Biote (BTMD) Q2 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/biote-btmd-q2-2026-earnings-call-transcript
- N4 | 2026-08-06 | www.nasdaq.com | biote Corp. (BTMD) Reports Break-Even Earnings for Q2 | https://www.nasdaq.com/articles/biote-corp-btmd-reports-break-even-earnings-q2
- N5 | 2026-08-05 | www.nasdaq.com | biote Q2 Earnings Call Highlights | https://www.nasdaq.com/articles/biote-q2-earnings-call-highlights
- N6 | 2026-05-06 | www.nasdaq.com | Biote (BTMD) Q1 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/biote-btmd-q1-2026-earnings-call-transcript
- N7 | 2026-05-06 | www.nasdaq.com | biote Corp. (BTMD) Q1 Earnings and Revenues Lag Estimates | https://www.nasdaq.com/articles/biote-corp-btmd-q1-earnings-and-revenues-lag-estimates
- N8 | 2026-04-29 | www.nasdaq.com | GE HealthCare Technologies (GEHC) Lags Q1 Earnings Estimates | https://www.nasdaq.com/articles/ge-healthcare-technologies-gehc-lags-q1-earnings-estimates
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


